ECSP22093652A - Compuestos de imidazopiridazina y usos de los mismos - Google Patents

Compuestos de imidazopiridazina y usos de los mismos

Info

Publication number
ECSP22093652A
ECSP22093652A ECSENADI202293652A ECDI202293652A ECSP22093652A EC SP22093652 A ECSP22093652 A EC SP22093652A EC SENADI202293652 A ECSENADI202293652 A EC SENADI202293652A EC DI202293652 A ECDI202293652 A EC DI202293652A EC SP22093652 A ECSP22093652 A EC SP22093652A
Authority
EC
Ecuador
Prior art keywords
compounds
imidazopyridazine compounds
imidazopyridazine
alk2 activity
cancer
Prior art date
Application number
ECSENADI202293652A
Other languages
English (en)
Inventor
Jun Pan
Liangxing Wu
Wenqing Yao
Yu Bai
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of ECSP22093652A publication Critical patent/ECSP22093652A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Dental Preparations (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos de Fórmula (I), métodos de uso de los compuestos para inhibir la actividad de ALK2 y composiciones farmacéuticas que comprenden dichos compuestos. Los compuestos son útiles para tratar, prevenir o mejorar enfermedades o trastornos asociados con la actividad de ALK2, tales como el cáncer.
ECSENADI202293652A 2020-06-12 2022-12-09 Compuestos de imidazopiridazina y usos de los mismos ECSP22093652A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063038410P 2020-06-12 2020-06-12

Publications (1)

Publication Number Publication Date
ECSP22093652A true ECSP22093652A (es) 2023-02-28

Family

ID=76971994

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202293652A ECSP22093652A (es) 2020-06-12 2022-12-09 Compuestos de imidazopiridazina y usos de los mismos

Country Status (17)

Country Link
US (2) US11840546B2 (es)
EP (1) EP4165051A1 (es)
JP (1) JP2023530088A (es)
KR (1) KR20230025434A (es)
CN (1) CN115956081A (es)
AR (1) AR122587A1 (es)
AU (1) AU2021288107A1 (es)
BR (1) BR112022025191A2 (es)
CA (1) CA3184811A1 (es)
CL (1) CL2022003453A1 (es)
CO (1) CO2022017969A2 (es)
EC (1) ECSP22093652A (es)
IL (1) IL298248A (es)
MX (1) MX2022015493A (es)
PE (1) PE20230491A1 (es)
TW (1) TW202214660A (es)
WO (1) WO2021252781A1 (es)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040089753A1 (en) 2000-06-28 2004-05-13 Holland Simon Joseph Wet milling process
BRPI0813625A2 (pt) * 2007-07-26 2014-12-23 Novartis Ag Imidazo-[1,2b]-piridozinas 2,3,7-substituídos para tratamento de doenças mediadas por alzk4 ou alk5
EA201000615A1 (ru) 2007-10-17 2010-12-30 Новартис Аг Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы)
CA2806655A1 (en) 2010-07-28 2012-02-02 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-b]pyridazines
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
ES2592267T3 (es) 2011-05-06 2016-11-29 Bayer Intellectual Property Gmbh Imidazopiridinas e imidazopiridazinas sustituidas y su uso
JP6542192B2 (ja) 2013-03-14 2019-07-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害剤およびその使用方法
TW201718581A (zh) 2015-10-19 2017-06-01 英塞特公司 作為免疫調節劑之雜環化合物
TWI763641B (zh) 2015-11-19 2022-05-11 美商英塞特公司 作為免疫調節劑之雜環化合物
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
MX2018007774A (es) 2015-12-22 2018-11-09 Incyte Corp Compuestos heterociclicos como inmunomoduladores.
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
LT3472167T (lt) 2016-06-20 2022-11-10 Incyte Corporation Heterocikliniai junginiai kaip imunomoduliatoriai
US20180016260A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
BR112019004992A2 (pt) 2016-09-14 2019-06-04 Univ Vanderbilt inibição da sinalização de bmp, compostos, composições e usos destes
WO2018053136A1 (en) 2016-09-15 2018-03-22 Armstrong World Industries, Inc. Ceiling system with air movement
US20180177784A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
MA47099A (fr) 2016-12-22 2021-05-12 Incyte Corp Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
KR102641030B1 (ko) 2016-12-22 2024-02-29 인사이트 코포레이션 Pd-l1 내재화 유도제로서의 테트라하이드로 이미다조[4,5-c]피리딘 유도체
ES2934230T3 (es) 2016-12-22 2023-02-20 Incyte Corp Derivados de benzooxazol como inmunomoduladores
BR112019014759A2 (pt) * 2017-01-18 2020-03-03 Vanderbilt University Compostos heterocíclicos fundidos como inibidores seletivos de bmp
WO2018165569A1 (en) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Therapeutic compounds and methods
CA3124088A1 (en) 2018-12-20 2020-06-25 Incyte Corporation Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2

Also Published As

Publication number Publication date
US11840546B2 (en) 2023-12-12
MX2022015493A (es) 2023-03-21
TW202214660A (zh) 2022-04-16
PE20230491A1 (es) 2023-03-23
CA3184811A1 (en) 2021-12-16
WO2021252781A1 (en) 2021-12-16
KR20230025434A (ko) 2023-02-21
AR122587A1 (es) 2022-09-21
US20240083918A1 (en) 2024-03-14
IL298248A (en) 2023-01-01
JP2023530088A (ja) 2023-07-13
AU2021288107A1 (en) 2022-12-15
CO2022017969A2 (es) 2023-02-27
CL2022003453A1 (es) 2023-05-26
CN115956081A (zh) 2023-04-11
BR112022025191A2 (pt) 2023-03-07
EP4165051A1 (en) 2023-04-19
US20210388003A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CO2024001285A2 (es) Compuestos tricíclicos como inhibidores de kras
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
CO2019007409A2 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos
CO2022000481A2 (es) Inhibidores de enzimas
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
ECSP21088111A (es) Analogos de 3–(5–metil–1,3–tiazol–2–il)–n–{(1r)–1–[2–(trifluor–metil)pirimidin–5–il]etil}benzamida
CL2022000005A1 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
CL2023000061A1 (es) Macrociclos y su uso
ECSP22009803A (es) [1,2,4]triazolo[1,5-c]quinazolin-5-aminas
CO2022018636A2 (es) Moduladores de il-17a
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
AR126854A1 (es) Compuestos macrocíclicos para el tratamiento de cáncer
UY39574A (es) Compuesto macrocíclico útil para tratar el cáncer y composición farmacéutica que lo contiene
CO2020013834A2 (es) Ciertos compuestos de pladienolida y métodos de uso
CL2023002633A1 (es) Derivados de uracilo como inhibidores de trpa1
BR112023025916A2 (pt) Combinação de um inibidor de braf e um inibidor de mek, uso de uma combinação, método para o tratamento ou profilaxia de câncer, composições farmacêuticas e invenção
CO2023008475A2 (es) Inhibidores de enzimas
ECSP22093652A (es) Compuestos de imidazopiridazina y usos de los mismos
DOP2022000203A (es) 3-fenoxiazetidin-1-il-pirazinas sustituidas con actividad antagonista gpr52
AR126389A1 (es) Compuestos tricíclicos como inhibidores de kras